Business Context and Reporting Period
BioMarin Pharmaceutical Inc. (BMRN) filed a Form 8-K on January 12, 2026, to disclose preliminary financial results presented at the 44th Annual J.P. Morgan Healthcare Conference. The report covers the fiscal year ended December 31, 2025. The company expects to report its official fourth-quarter and full-year 2025 results in February 2026.
Key Financial Metrics
- Total Revenue (2025): Approximately $3.2 billion (unaudited).
- VOXZOGO Revenue (2025): Approximately $920 million (unaudited).
- Asset Write-Down (ROCTAVIAN): Expected to be between $230 million and $260 million in the fourth quarter of 2025.
- Impact on Non-GAAP EPS: The write-down is expected to reduce Non-GAAP Diluted EPS by $(0.60) to $(0.64) per share, assuming approximately 200 million weighted-average diluted shares outstanding.
- Other Metrics: The filing does not provide clear values for GAAP net income, operating margins, cash flow, debt levels, or liquidity positions.
Material Changes and Unusual Items
The primary material change disclosed is the anticipated asset write-down related to ROCTAVIAN. This non-cash charge is an unusual item expected to significantly impact reported earnings for the year ended December 31, 2025. Excluding the impact of this write-down, the company's previously issued 2025 full-year financial guidance for Non-GAAP Diluted EPS remains unchanged.
Guidance, Outlook, and Risks
BioMarin maintains its prior Non-GAAP Diluted EPS guidance for 2025, excluding the ROCTAVIAN write-down. The company cautions that the disclosed figures are preliminary, unaudited, and subject to normal accounting closing procedures. Actual results may differ materially from these estimates. The filing references standard risk factors detailed in the company's Form 10-Q for the quarter ended September 30, 2025, including uncertainties related to accounting finalization and forward-looking statements.
Investor Verification Checklist
- Verify the final audited total revenue and ROCTAVIAN write-down amount in the February 2026 earnings release.
- Confirm the exact impact of the write-down on GAAP Net Income versus Non-GAAP Income.
- Review the official 2025 annual report for updated cash flow, debt, and liquidity metrics not included in this 8-K.
- Assess the strategic rationale and future prospects for ROCTAVIAN following the write-down announcement.